Related Experiment Videos
Hepatitis B vaccine: further studies in children with previously acquired hepatitis B surface antigenemia
Insights
Hepatitis B vaccination in HBsAg-positive Senegalese children was safe but ineffective at reducing chronic carriers. The study found antigen presence and older age increased chronic carrier risk.
Area of Science:
- Pediatrics
- Immunology
- Infectious Diseases
Background:
- Hepatitis B virus (HBV) infection is a significant global health concern.
- Chronic HBV infection in children can lead to serious liver disease.
- Identifying effective interventions for HBsAg-positive children is crucial.
Purpose of the Study:
- To evaluate the safety and efficacy of an inactivated hepatitis B vaccine in HBsAg-positive Senegalese children.
- To assess the impact of vaccination on the prevalence of chronic hepatitis B surface antigen (HBsAg) carriers.
Main Methods:
- A randomized controlled trial involving 31 HBsAg-positive children aged 3-24 months receiving hepatitis B vaccine.
- A control group of 18 HBsAg-positive children received diphtheria-tetanus-polio vaccine.
- Follow-up for 12 months to determine HBsAg carrier status.
Main Results:
- Hepatitis B vaccination was safe in HBsAg-positive infants.
- Vaccination did not significantly reduce the prevalence of HBsAg chronic carriers compared to the control group (48.4% vs. 66.7%).
- Hepatitis B antigen presence and older age at enrollment were identified as risk factors for developing a chronic carrier state.
Conclusions:
- Inactivated hepatitis B vaccination is not an effective strategy for reducing chronic HBsAg carriage in already infected children.
- Early detection and management strategies are essential for HBsAg-positive children.
- Further research is needed to explore alternative interventions for this population.
Abstract:
Three doses of inactivated hepatitis B vaccine were given at 1-month intervals to 31 hepatitis B surface antigen (HBsAg)-positive Senegalese children aged between 3 and 24 months. A control group of 18 HBsAg-positive Senegalese children received diphtheria-tetanus-polio vaccine. Immunization of HBsAg-positive infants with hepatitis B vaccine was safe but inefficient. After a 12-month follow-up, the prevalence of HBsAg chronic carriers was not significantly reduced in the hepatitis B vaccine group as compared with the control group: 48.4 and 66.7%, respectively. The presence of hepatitis B antigen was found to be a major risk factor for HBsAg-positive children to develop a chronic carrier state. The risk of developing an HBsAg chronic carrier state was also related to advancing age at time of enrollment in the study.